Press Releases

Singapore, March 21, 2024– WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it received four awards at the 2024 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony, and that the company’s President of Global Biologics Development and Operations and Chief Technology Officer (CTO), Dr. Weichang Zhou, was honored with CTO of the Year 2023.

WuXi Biologics stood out in the following categories, achieving its highest number of awards since first receiving ABEA recognition in 2017:

• Best Contract Development and Manufacturing Organization Award
• Bioprocessing Excellence in Greater China Region
• Best Bioprocessing Supplier Award
• Best Aseptic Fill-Finish & Packaging CMO of the Year

Sponsored by IMAPAC, a leading consulting firm in the biopharmaceutical industry, the ABEA seeks to recognize the outstanding achievements of top leaders in biomanufacturing, biologistics and clinical trials, applauding extraordinary leaders and trend-setters of today and inspiring innovators of tomorrow.

WuXi Biologics provides end-to-end services for nearly 600 clients worldwide. With its innovative technologies, world-class quality systems, extensive global manufacturing network and proven success rates, the company enables clients to advance their biologics into the clinic and on to the market.

The company’s drug product GMP manufacturing services have been validated by major regulatory agencies, including the FDA, EMA and China NMPA, as well as by over 1,000 quality audits from global clients. An overall success rate of 99%+ has been achieved for more than 1,700 batches of drug products.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “The multiple awards WuXi Biologics received are a true testament to the value we have created for our clients and for the industry. With an unwavering commitment to excellence and quality, a strong leadership team and dedicated people, we will continue to enable our clients to accelerate breakthrough treatments to benefit patients worldwide.”

Dr. Weichang Zhou, President of Global Biologics Development and Operations & CTO of WuXi Biologics received the award

Dr. Weichang Zhou won CTO of the Year award for his remarkable leadership and achievements in pioneering technology innovations to expedite biologics development and manufacturing.

Dr. Zhou said, “I am honored to receive this award. It is exciting to be part of the advancement of more flexible, productive, and efficient approaches as our team at WuXi Biologics works to enhance technologies that help increase the global accessibility and affordability of biologic therapies. “

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Business

info@wuxibiologics.com

Media

PR@wuxibiologics.com